Myeloid cell heterogeneity in cancer: not a single cell alike
- Author
- Mate Kiss, Sofie Van Gassen (UGent) , Kiavash Movahedi, Yvan Saeys (UGent) and Damya Laoui
- Organization
- Abstract
- Tumors of various histological origins show abundant infiltration of myeloid cells from early stages of disease progression. These cells have a profound impact on antitumor immunity and influence fundamental processes that underlie malignancy, including neoangiogenesis, sustained cancer cell proliferation, metastasis and therapy resistance. For these reasons, development of therapeutic approaches to deplete or reprogram myeloid cells in cancer is an emerging field of interest. However, knowledge about the heterogeneity of myeloid cells in tumors and their variability between patients and disease stages is still limited. In this review, we summarize the most recent advances in our understanding about how the phenotype of tumor-associated macrophages, monocytes, neutrophils, myeloid-derived suppressor cells and dendritic cells is dictated by their ontogeny, activation status and localization. We also outline major open questions that will only be resolved by applying high-dimensional single-cell technologies and systems biology approaches in the analysis of the tumor microenvironment.
- Keywords
- TUMOR-ASSOCIATED MACROPHAGES, TISSUE-RESIDENT MACROPHAGES, ANTIGEN-PRESENTING CELLS, HUMAN LUNG-CANCER, DENDRITIC CELLS, SUPPRESSOR-CELLS, MASS CYTOMETRY, MELANOMA PATIENTS, IMMUNE-RESPONSES, BONE-MARROW, Tumor-associated macrophage, TAM, Myeloid-derived suppressor cell, MDSC, Tumor-associated dendritic cell, TADC, Single-cell RNA sequencing, Mass, cytometry, Myeloid cell heterogeneity, Tumor microenvironment
Downloads
-
(...).pdf
- full text
- |
- UGent only
- |
- |
- 833.09 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8582837
- MLA
- Kiss, Mate, et al. “Myeloid Cell Heterogeneity in Cancer: Not a Single Cell Alike.” CELLULAR IMMUNOLOGY, vol. 330, 2018, pp. 188–201, doi:10.1016/j.cellimm.2018.02.008.
- APA
- Kiss, M., Van Gassen, S., Movahedi, K., Saeys, Y., & Laoui, D. (2018). Myeloid cell heterogeneity in cancer: not a single cell alike. CELLULAR IMMUNOLOGY, 330, 188–201. https://doi.org/10.1016/j.cellimm.2018.02.008
- Chicago author-date
- Kiss, Mate, Sofie Van Gassen, Kiavash Movahedi, Yvan Saeys, and Damya Laoui. 2018. “Myeloid Cell Heterogeneity in Cancer: Not a Single Cell Alike.” CELLULAR IMMUNOLOGY 330: 188–201. https://doi.org/10.1016/j.cellimm.2018.02.008.
- Chicago author-date (all authors)
- Kiss, Mate, Sofie Van Gassen, Kiavash Movahedi, Yvan Saeys, and Damya Laoui. 2018. “Myeloid Cell Heterogeneity in Cancer: Not a Single Cell Alike.” CELLULAR IMMUNOLOGY 330: 188–201. doi:10.1016/j.cellimm.2018.02.008.
- Vancouver
- 1.Kiss M, Van Gassen S, Movahedi K, Saeys Y, Laoui D. Myeloid cell heterogeneity in cancer: not a single cell alike. CELLULAR IMMUNOLOGY. 2018;330:188–201.
- IEEE
- [1]M. Kiss, S. Van Gassen, K. Movahedi, Y. Saeys, and D. Laoui, “Myeloid cell heterogeneity in cancer: not a single cell alike,” CELLULAR IMMUNOLOGY, vol. 330, pp. 188–201, 2018.
@article{8582837, abstract = {{Tumors of various histological origins show abundant infiltration of myeloid cells from early stages of disease progression. These cells have a profound impact on antitumor immunity and influence fundamental processes that underlie malignancy, including neoangiogenesis, sustained cancer cell proliferation, metastasis and therapy resistance. For these reasons, development of therapeutic approaches to deplete or reprogram myeloid cells in cancer is an emerging field of interest. However, knowledge about the heterogeneity of myeloid cells in tumors and their variability between patients and disease stages is still limited. In this review, we summarize the most recent advances in our understanding about how the phenotype of tumor-associated macrophages, monocytes, neutrophils, myeloid-derived suppressor cells and dendritic cells is dictated by their ontogeny, activation status and localization. We also outline major open questions that will only be resolved by applying high-dimensional single-cell technologies and systems biology approaches in the analysis of the tumor microenvironment.}}, author = {{Kiss, Mate and Van Gassen, Sofie and Movahedi, Kiavash and Saeys, Yvan and Laoui, Damya}}, issn = {{0008-8749}}, journal = {{CELLULAR IMMUNOLOGY}}, keywords = {{TUMOR-ASSOCIATED MACROPHAGES,TISSUE-RESIDENT MACROPHAGES,ANTIGEN-PRESENTING CELLS,HUMAN LUNG-CANCER,DENDRITIC CELLS,SUPPRESSOR-CELLS,MASS CYTOMETRY,MELANOMA PATIENTS,IMMUNE-RESPONSES,BONE-MARROW,Tumor-associated macrophage,TAM,Myeloid-derived suppressor cell,MDSC,Tumor-associated dendritic cell,TADC,Single-cell RNA sequencing,Mass,cytometry,Myeloid cell heterogeneity,Tumor microenvironment}}, language = {{eng}}, pages = {{188--201}}, title = {{Myeloid cell heterogeneity in cancer: not a single cell alike}}, url = {{http://doi.org/10.1016/j.cellimm.2018.02.008}}, volume = {{330}}, year = {{2018}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: